American Association of Pharmaceutical Scientists

American Association of Pharmaceutical Scientists (AAPS) and Pharmacometrics, Office of Clinical Pharmacology, Food and Drug Administration (FDA) have a Cooperative Research and Development Agreement (CRADA) to build a quantitative Alzheimer’s Disease Model. AAPS is seeking fellows who are interested in applying quantitative ‘learning’ approaches for solving drug development and regulatory challenges. Specifically, the incumbent will work with the FDA Pharmacometrics group (Silver Spring, MD, USA) to develop and apply Alzheimer’s Disease Model to drug development. The fellowship is for 2 years. Requirements include an earned Pharm.D., Ph.D., M.D. or other professional doctorate related to pharmaceutical sciences or statistics. Clinical and pharmaceutical scientists with a good knowledge of pharmacokinetic and pharmacodynamic principles, an experience in mixed effects modeling including software skills (SAS, Splus, NONMEM, etc) or a statistician with a good knowledge of trial design and analyses principles with an interest in advanced innovative methods to explore clinical trial data are eligible for this fellowship. Proficiency with standard software (NONMEM, SAS or SPlus/R) is a must. This fellowship could also be a good opportunity for academicians who are willing to take 2 years of sabbatical leave. Good communication and writing skills are critical. Opportunities to learn and contribute in a dynamic team, to gain first-hand experience with regulatory aspects of Pharmacometrics, and to conduct and publish research in related areas are abundant. Candidates will need to be US permanent residents or citizens. Please forward your resume to: AAPS Attention: CRADA—Alzheimer’s Disease Model 2107 Wilson Boulevard, Suite 700 Arlington, VA 22201 crada@aaps.org www.aapspharmaceutica.com/crada Deadline for submissions: June 30, 2008

American Association of Pharmaceutical Scientists (AAPS) and Pharmacometrics, Office of Clinical Pharmacology, Food and Drug Administration (FDA) have a Cooperative Research and Development Agreement (CRADA) to build a quantitative Alzheimer’s Disease Model. AAPS is seeking fellows who are interested in applying quantitative ‘learning’ approaches for solving drug development and regulatory challenges. Specifically, the incumbent will work with the FDA Pharmacometrics group (Silver Spring, MD, USA) to develop and apply Alzheimer’s Disease Model to drug development. The fellowship is for 2 years. Requirements include an earned Pharm.D., Ph.D., M.D. or other professional doctorate related to pharmaceutical sciences or statistics. Clinical and pharmaceutical scientists with a good knowledge of pharmacokinetic and pharmacodynamic principles, an experience in mixed effects modeling including software skills (SAS, Splus, NONMEM, etc) or a statistician with a good knowledge of trial design and analyses principles with an interest in advanced innovative methods to explore clinical trial data are eligible for this fellowship. Proficiency with standard software (NONMEM, SAS or SPlus/R) is a must. This fellowship could also be a good opportunity for academicians who are willing to take 2 years of sabbatical leave. Good communication and writing skills are critical. Opportunities to learn and contribute in a dynamic team, to gain first-hand experience with regulatory aspects of Pharmacometrics, and to conduct and publish research in related areas are abundant. Candidates will need to be US permanent residents or citizens. Please forward your resume to: AAPS Attention: CRADA—Alzheimer’s Disease Model 2107 Wilson Boulevard, Suite 700 Arlington, VA 22201 crada@aaps.org http://www.aapspharmaceutica.com/crada Deadline for submissions: June 30, 2008

American Association of Pharmaceutical Scientists (AAPS) and Pharmacometrics, Office of Clinical Pharmacology, Food and Drug Administration (FDA) have a Cooperative Research and Development Agreement (CRADA) to build a quantitative Alzheimer’s Disease Model. AAPS is seeking fellows who are interested in applying quantitative ‘learning’ approaches for solving drug development and regulatory challenges. Specifically, the incumbent will work with the FDA Pharmacometrics group (Silver Spring, MD, USA) to develop and apply Alzheimer’s Disease Model to drug development. The fellowship is for 2 years. Requirements include an earned Pharm.D., Ph.D., M.D. or other professional doctorate related to pharmaceutical sciences or statistics. Clinical and pharmaceutical scientists with a good knowledge of pharmacokinetic and pharmacodynamic principles, an experience in mixed effects modeling including software skills (SAS, Splus, NONMEM, etc) or a statistician with a good knowledge of trial design and analyses principles with an interest in advanced innovative methods to explore clinical trial data are eligible for this fellowship. Proficiency with standard software (NONMEM, SAS or SPlus/R) is a must. This fellowship could also be a good opportunity for academicians who are willing to take 2 years of sabbatical leave. Good communication and writing skills are critical. Opportunities to learn and contribute in a dynamic team, to gain first-hand experience with regulatory aspects of Pharmacometrics, and to conduct and publish research in related areas are abundant. Candidates will need to be US permanent residents or citizens. Please forward your resume to: AAPS Attention: CRADA—Alzheimer’s Disease Model 2107 Wilson Boulevard, Suite 700 Arlington, VA 22201 crada@aaps.org http://www.aapspharmaceutica.com/crada Deadline for submissions: June 30, 2008

Alpha-tocopherol (AT) is the vitamin E homologue with the highest in vivo biological activity. AT protects against the carcinogenic and mutagenic activity of ionizing radiation and chemical agents, and possibly against UV-induced cutaneous damage. For stability consideration, alpha-tocopherol is usually used as its prodrug ester, alpha-tocopherol acetate (ATA), which once absorbed into the skin is hydrolyzed to alpha-tocopherol, the active form. The objective of this research was to characterize in vitro the permeation properties of ATA from various solutions and gel formulations. Permeation studies were conducted using modified Franz diffusion cells and human cadaver skin as the membrane. Specifically, 5% (w/w) alpha-tocopherol acetate was formulated in the following vehicles: ethanol, isopropyl myristate, light mineral oil, 1% Klucel gel in ethanol, and 3% Klucel gel in ethanol (w/w). The receiver temperature was 37 degrees C. Samples from the receiver were collected at 2, 4, 6, 8, 12, 24, 30, 36, and 48 hours and analyzed by HPLC for concentrations of alpha-tocopherol acetate and alpha-tocopherol. The permeabilities of ATA through human cadaver skin were 1.0x10(-4), 1.1x10(-2), 1.4x10(-4), 2.1x10(-4), and 4.7x10(-4) cm/h for the ethanol solution, isopropyl myristate solution, light mineral oil solution, 1% Klucel gel, and 3% Klucel gel, respectively. The results show that the formulation had relatively minor effects on the permeability coefficients of ATA through cadaver skin in all cases except for the isopropyl myristate solution.